acute GVHD are the main causes of liver dysfunction in the first 100 days after BMT, any liver disease persisting Long-term effects after blood or bone marrow transafter day 100 is usually due to chronic GVHD, chronic plantation (BMT) are emerging as an important issue, hepatitis C virus (HCV) infection 4 or iron overload. 5 There as more patients are included in BMT programmes and is little information about the incidence and prognosis of as this procedure becomes more successful. Long-term chronic liver disease after BMT. The importance of HCV liver dysfunction, mainly due to chronic graft-versusinfection in long-term liver dysfunction after allogeneic host disease or hepatitis C virus infection, is a well-BMT has recently been reported. 4, 6, 7 Nevertheless, the diagknown complication. Nevertheless, the diagnosis of liver nosis is sometimes difficult in this group of patients as more disease in this patient group is sometimes difficult and, than one cause can be present. Moreover in as many as despite adequate studies, it may remain undetected. A 5-10% of cases of long-term liver dysfunction, the cause novel hepatitis-associated virus, hepatitis G virus remains unknown. to the Flaviviridae family and is known to be parand HGV 9 have recently been identified. The molecular enterally transmitted, although there is no clear evicharacterization of these agents has shown a more than 95% dence to implicate this agent in causing acute or chronic homology at the nucleotide level between GBV-C and hepatitis. We report a patient who developed mild, but HGV, demonstrating that they represent different isolates persistent, abnormalities in transaminases for 2 years of the same virus. Sequence analysis of the HGV genome after an autologous BMT. HGV RNA was detected in reveals that it belongs to the Flaviridae family. 10 The agent both serum and liver. HGV RNA persisted in serum for is known to be parenterally transmitted, and a high prevaat least 8 months. No other known hepatitis virus was lence of HGV RNA has been found in subjects with frefound. This report provides the first direct evidence of quent parenteral exposure including intravenous drug a patient with long-term liver abnormalities after a users, 11 patients on hemodialysis 12 and patients with hemo-BMT in whom the only known hepatitis virus isolated philia. 13 HGV RNA has been found in 1-2% of voluntary was the HGV.
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donors in the USA and is hence more prevalent in the genKeywords: hepatitis G virus; liver; bone marrow transeral population than HCV. 14 Despite these rapidly increasplant; long-term effects ing virological, molecular and epidemiological discoveries, the clinical implications of this new agent in acute and chronic hepatitis remain largely unresolved. Some authors Liver function abnormalities are frequent after either autohave reported cases of fulminant hepatitis which cannot be logous or allogeneic bone marrow transplantation, 1 diagnosed as hepatitis A, B, C, D or E, associated with although causes and clinical behavior differ in both types of HGV, 15 but other investigators argue that there is not suftransplant. [2] [3] [4] The differential diagnoses include acute and ficient evidence to support the role of HGV infection in chronic graft-versus-host disease (GVHD), veno-occlusive acute or chronic liver disease.
14 disease of the liver (VOD), toxic liver cell damage caused Patients who have undergone a BMT are exposed to a by chemotherapy, and viral infections caused by hepatitis large number of transfusions, and HGV may thus infect B and C viruses, cytomegalovirus, Epstein-Barr virus, etc.
these patients, although, to date, no information is availWhile liver toxicity following cytoreductive therapy and able. We report here the first detection of HGV in the serum and liver of a patient after an autologous BMT. Case report and methods as previously described.
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A neutrophil engraftment (Ͼ0.5 × 10 3 /l) occurred on day +12. A delayed platelet engraftment took place and the patient required platelet A 43-year-old Caucasian woman was found to have acute myeloblastic leukemia (FAB M1) in April 1993. There was transfusions until day +48. Due to a very bad recovery after platelet transfusions during the acute period, the patient no history of prior liver disease, transfusions, surgery, hospitalizations, or other relevant medical history, save for an received platelets daily and high doses of intravenous inmunoglobulins (25 g/day for 5 days) (Polyglobin Bayer, Baruntreated scoliosis diagnosed 4 years before admission. On admission, the white blood cell count (WBC) was celona, Spain). Platelet transfusions were stopped on day +46, and she reached Ͼ50 000 platelets on day +74 and 2.8 × 10 3 /l with 12% blasts, hemoglobin 90 g/l, AST 31 IU/l (normal range 0-39) and ALT 41 IU/l (0-35). The Ͼ100 000 on day +157. During this period, the patient was exposed to blood products from 148 donors. There were no alkaline phosphatase (AP), GGT, immunoglobulins, prothrombin time and albumin values were normal. HBsAg, major toxicities after the transplant, and the patient currently remains well with complete hematological remission antiHBs, and antiHBc, as well as a second generation ELISA test for HCV, were negative. A bone marrow aspir-28 months after the autologous bone and blood marrow transplantation. Four months after transplant, the patient ate showed a blastic infiltration (65%) with cells which were positive for myeloperoxidase and for CD33, CD34, developed abnormal ALT levels, which persisted in almost all examinations ( 158 IU/l. Bilirubin, gammaglobulin and AP levels have been in the normal range, while both GGT and AST have days) and achieved a complete hematological remission after the second course. Another intensification course of also altered during this period. The presence of anti-nuclear antibodies, anti-LKM-1, anti-smooth muscle, anti-mitomitoxantrone (12 mg/m 2 /3 days) and cytarabine (1 g/m 2 /12 h/4 days) was administered before the patient was referred chondrial antibodies and anti-ENA was also evaluated, with negative results. to our hospital for autologous bone marrow transplantation.
No serious infectious complication or other major organ
For the detection of HBV in serum by PCR, HBV-DNA was isolated from 200 l of serum after proteinase K toxicity occurred after the induction and consolidation courses, with the exception of refractoriness to platelet (1 mg/ml) and 1% sodium dodecyl sulfate (SDS) digestion at 37°C for 2 h. Nucleic acids were extracted twice with transfusions. During this period, the patient developed an increase in ALT levels with a peak after the second inducphenol:chloroform (1:1) and once with ether, collected through 2 M ammonium acetate and ethanol precipitation tion course (ALT 199 IU, AST 117, AP 172, GGT 69) ( Figure 1 ). Over this period, the patient was exposed to and dissolved in 30 l of distilled water. Polymerase chain reaction (PCR) was performed in duplicate for each sample blood products from 32 donors. The evaluation before bone marrow transplantation showed slightly abnormal liver in a 50 ml assay containing 5 l of serum DNA sample, 10 mM Tris-HCl (pH 8. 10 l of the first PCR product were amplified using the The total RNA obtained from sera, the last cell wash, and 1 g of tissue RNA was amplified by RT-PCR, using primers B1: 5′-GGAGGCTGTAGGCATAAATTGGTCT-GCGC-3′ at positions 1777-1800 and BC1: 5′-GGspecific primers from the putative helicase/NS3 gene, designed according to the HGV sequence reported by AAAGAAGTCAGAAGGCAA-3′ at positions [1955] [1956] [1957] [1958] [1959] [1960] [1961] [1962] [1963] [1964] [1965] [1966] [1967] [1968] [1969] [1970] [1971] [1972] [1973] [1974] . Nucleotide positions of the primers used for HBV-DNA Simons et al, 8 which amplifies a 272 bp fragment, and from the 5′ noncoding region according to the sequence reported detection are given according to Ono et al. 17 Positive and negative controls were tested in each PCR run.
by Leary et al, 10 which amplifies a 320 bp fragment. The antisense oligonucleotides AMS3 (NS3 region) and S1 (5′ For HCV studies total RNA from serum was isolated as described.
18 HCV RNA was tested by reverse-transcription noncoding region) were used to prime cDNA synthesis of the genomic HGV strand. After an RNA denaturation step and nested PCR. The oligonucleotide primers used were selected according to the high conserved 5′ noncoding (5 min at 95°C), AMV-RT was added, and reverse transcription was carried out at 42°C for 30 min. Finally, region of the HCV genome. 19 For external primers the following sequences were used: sense, nucleotides 18-38, AMV-RT was inactivated by heating at 95°C for 15 min. For NS3 amplification, the first 35 cycle PCR rounds 5′-GGCGACACTCCACCATAGATC-3′; and antisense, nucleotides 322-344, 5′-CATGGTGCACGGTCTACwere carried out using the AMS1 primer at 94°C for 1 min and 30 s, 55°C for 1 min and 30 s and 72°C for 1 min, GAGA-3′. Internal primers were as follows: sense, nucleotides 51-71, 5′-GCAACTACTGTCTTGACGCAG-3′; with a final extension step at 72°C for 7 min. The second PCR round was performed under the same conditions, with and antisense, nucleotides 289-310, 5′-TGCCAA-GCACCCTATCAGGCAG-3′. A denaturation step was 10% of the first PCR product, using the AMS2 and AMS4 primers. For the 5′ noncoding region amplification, the S1 carried out before the HCV cDNA synthesis to reduce RNA secondary structure. RNA was reverse-transcribed with 8 U primer was used in the first PCR. The conditions for the first 35 PCR cycles were 95°C 1 min, 50°C 1 min and 72°C of avian myeloblastic virus reverse transcriptase using the external antisense primer, at 43°C for 30 min. The first PCR 1 min. For the second PCR, 10% of the first PCR product was amplified using the same conditions as for the first round was performed with the total cDNA mixture adding the external sense primer and 2 U of Taq polymerase in a PCR round and the primers S2 and A2 (sequence and position of the primers used are given in Table 1 ). The sensifinal volume of 100 l. The amplification was carried out at 94°C for 0.6 min, 56°C for 0.7 min and 68°C for 3 min tivity of the PCR assay for HGV RNA detection was estimated to be 10 3 -10 4 genomes/ml as tested using HGVfor 25 cycles. Then, 10 l of the first PCR product was amplified as described previously for 35 cycles with the RNA in vitro transcribed from a plasmid containing the complete 5′ noncoding region of the HGV genome. After inner primers. Positive (a serum sample from a chronic HCV carrier with abnormal ALT levels) and negative conamplification of the genomic HGV-RNA strand, a positive signal was found in all serum samples tested (Figure 1 ), as trols were tested in each PCR run. No HBV-DNA or HCV-RNA was detected in any of the serum samples tested well as in the liver biopsy with both NS3 and 5′ noncoding region primers. No substantial changes in HGV-RNA con- (Figure 1) .
A liver biopsy was performed on day +716 after transcentration (stimulated using a positive HGV-RNA control of known concentration) were observed in all serum plant. It was processed for histological diagnosis and immunohistochemistry following standard procedures. samples tested. In contrast, all PBMC samples were always negative with both sets of primers ( Figure 2 ). Examination of the liver tissue showed areas of inactive portoseptal fibrosis, irregularly distributed. At the lobular To confirm the specificity of the detection of HGV in serum and liver, the PCR products were cloned in the PCR level, there was mixed steatosis of macrovacuolar predominance (grade II/IV), without selective distribution, together TM vector (TA cloning KIT; Invitrogen Corporation, San Diego, CA, USA), and at least three positive clones from with focal small lymphohistiocytic aggregates and some acidophilic bodies, randomly distributed. Also observed were glycogenated nuclei, hepatocellular hydropism, Table 1 Sequence and nucleotide position of the primers used in HGV alcoholic-like hyalin and mild siderosis in the periportal RNA amplification hepatocytes. Neither portal lymphoid nodules nor cholangitic lesions were found. No signs of chronic graft-versus-
5′ Noncoding region
host disease were observed. The histological diagnosis was steatohepatitis with inactive fibrosis and mild siderosis.
Nucleotide sequence Position
The liver biopsy was tested for the presence of cytomegalovirus, Epstein-Barr virus, herpes virus, HCV antigens, S1 each PCR product were sequenced by the dideoxynucleopublished in both the 5′ noncoding and the NS3 regions. This result suggests that several HGV genotypes may exist. tide chain termination method (Sequenase Version 2.0; USB, Cleveland, OH, USA). Sequence analysis showed an
On the other hand, the lack of detection of HGV RNA in PBMCs may imply that HGV is not a lymphotropic virus homology higher than 95% at the nucleotide level among clones from both the NS3 and 5′ noncoding regions. In like HCV, although this will need further research. All the above-stated results demonstrate that HGV may contrast, comparison with the sequence reported by Leary showed 78% homology in the noncoding region and 80% chronically infect patients after BMT. However, the possible clinical relevance of the HGV infection is not clear. in the NS3 region (data not shown).
Thus, our patient began with abnormal liver function tests 3 months after the autologous blood and progenitor stem cell transplantation and persisted with these high ALT Discussion levels in nearly all evaluations for 2 years. Unfortunately, samples from this patient before AML diagnosis or BMT Long-term liver dysfunction after BMT is principally caused by chronic graft-versus-host disease and viral infecwere not available, and we do not know if the patient acquired the infection during the first induction courses, tions, mainly due to HCV. Since the introduction of sensitive tests for the identification of HCV-positive donors, the during the transplant, or if she had been infected before the diagnosis of AML. Nevertheless, as this patient was incidence of transfusion-associated disease has diminished. There are still, however, some patients who develop liver exposed to a high number of donors, the most plausible route for infection acquisition is the transfusions, although function abnormalities after BMT without a clearly identified cause. A new hepatitis virus, hepatitis G virus, has infection due to use of contaminated commercial immunoglobulins cannot be excluded. In this context, Nübling recently been independently isolated by two different groups.
8,9 HGV-related sequences have been detected in et al. 20 have demonstrated in a recent communication the presence of HGV in the commercial preparation of patients with fulminant hepatis without evidence of infection with other hepatotropic viruses, 15 patients with chronic immunoglobulins. With respect to the ALT profile, the first ALT peak hepatitis C, 11 as well as in patients without evidence of liver disease. 9 However, little is known about the pathogenesis, occurred after the first induction course and can be attributed to chemotherapy toxicity. However, as the patient epidemiological prevalence, or clinical significance of HGV infection.
was exposed to blood products from 32 donors over this period, the possibility that this ALT peak was caused by To our knowledge, no report has been published concerning HGV in a BMT patient. We have detected HGV RNA an acute HGV infection cannot be ruled out. After BMT, the ALT levels became normal, but increased again 3-4 in a patient after BMT; HGV RNA was constantly detected in all serum samples obtained within a period of 8 months.
months after the transplant, when immune reconstitution after an autologous BMT classically begins. 21 This finding Furthermore, HGV RNA was detected in the liver biopsy while other hepatotropic viruses (HBV, HCV, EBV, etc) supports an immunologically related mechanism of liver damage by HGV. However, the histological lesions were not. The specificity of the HGV RNA detection was confirmed by cloning and sequencing the PCR products.
observed fit into the so-called non-alcoholic steatohepatitis. 22 Accordingly, any clinical conditions associated The sequence data obtained shows a 20% difference at the nucleotide level with respect to the sequences previously with this pathology (such as overweight or diabetes) should
